Wenyong Chen

5.0k total citations · 1 hit paper
65 papers, 3.9k citations indexed

About

Wenyong Chen is a scholar working on Molecular Biology, Hematology and Geriatrics and Gerontology. According to data from OpenAlex, Wenyong Chen has authored 65 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 17 papers in Hematology and 12 papers in Geriatrics and Gerontology. Recurrent topics in Wenyong Chen's work include Chronic Myeloid Leukemia Treatments (14 papers), Sirtuins and Resveratrol in Medicine (11 papers) and Histone Deacetylase Inhibitors Research (9 papers). Wenyong Chen is often cited by papers focused on Chronic Myeloid Leukemia Treatments (14 papers), Sirtuins and Resveratrol in Medicine (11 papers) and Histone Deacetylase Inhibitors Research (9 papers). Wenyong Chen collaborates with scholars based in United States, China and United Kingdom. Wenyong Chen's co-authors include Stephen B. Baylin, Michael Roth, Tim M. Townes, Hongfeng Yuan, Ravi Bhatia, Wei Gu, Ray-Whay Chiu Yen, David H. Wang, Jianyuan Luo and Zhiqiang Wang and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Wenyong Chen

60 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Suppressor HIC1 Directly Regulates SIRT1 to Modulate p53-Dependent DNA-Damage Responses

2005 530 citations Wenyong Chen, David H. Wang et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wenyong Chen United States	29	2.1k	989	781	709	386	65	3.9k
Lin Xiao China	31	2.5k 1.2×	459 0.5×	554 0.7×	1.0k 1.4×	82 0.2×	87	4.2k
Yuji Nakayama Japan	39	2.5k 1.2×	141 0.1×	308 0.4×	725 1.0×	102 0.3×	191	4.2k
Kevin Gardner United States	31	2.1k 1.0×	188 0.2×	215 0.3×	649 0.9×	146 0.4×	101	3.6k
Yue Huang China	34	2.1k 1.0×	82 0.1×	257 0.3×	744 1.0×	321 0.8×	101	3.6k
Martin J. Walsh United States	43	5.1k 2.4×	114 0.1×	450 0.6×	639 0.9×	243 0.6×	105	6.5k
Deirdre A. Nelson United States	21	1.9k 0.9×	133 0.1×	1.3k 1.7×	554 0.8×	54 0.1×	45	3.2k
Zhen Lü United States	40	2.9k 1.3×	88 0.1×	730 0.9×	963 1.4×	65 0.2×	160	4.8k
Carlo Leonetti Italy	41	3.2k 1.5×	77 0.1×	197 0.3×	1.8k 2.5×	182 0.5×	129	5.1k
Paul O. Hassa Switzerland	36	4.2k 2.0×	367 0.4×	270 0.3×	4.0k 5.7×	57 0.1×	43	6.8k
Weiliang Xia China	27	1.4k 0.7×	290 0.3×	179 0.2×	489 0.7×	35 0.1×	48	2.7k

Countries citing papers authored by Wenyong Chen

Since Specialization

Citations

This map shows the geographic impact of Wenyong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenyong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenyong Chen more than expected).

Fields of papers citing papers by Wenyong Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenyong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenyong Chen. The network helps show where Wenyong Chen may publish in the future.

Co-authorship network of co-authors of Wenyong Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Wenyong Chen. A scholar is included among the top collaborators of Wenyong Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenyong Chen. Wenyong Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Chunxiao, Xiwei Wu, Jinhui Wang, et al.. (2024). Sex-dependent differences in hematopoietic stem cell aging and leukemogenic potential. Oncogene. 44(2). 64–78. 4 indexed citations

Tan, Xi, et al.. (2024). Deciphering the pharmacological mechanism of Radix astragali for allergic rhinitis through network pharmacology and experimental validation. Scientific Reports. 14(1). 29873–29873. 6 indexed citations

Zhang, Chunxiao, Charles Warden, Zheng Liu, et al.. (2022). Loss of SIRT1 inhibits hematopoietic stem cell aging and age-dependent mixed phenotype acute leukemia. Communications Biology. 5(1). 396–396. 15 indexed citations

Zhang, Chunxiao, Zhiqiang Wang, Steven Vonderfecht, et al.. (2021). An aging mouse model of human chronic myeloid leukemia. Oncogene. 40(17). 3152–3163. 6 indexed citations

Tan, Xi, et al.. (2020). Erchen Plus Huiyanzhuyu Decoction Inhibits the Growth of Laryngeal Carcinoma in a Mouse Model of Phlegm‐Coagulation‐Blood‐Stasis Syndrome via the STAT3/Cyclin D1 Pathway. Evidence-based Complementary and Alternative Medicine. 2020(1). 2803496–2803496. 8 indexed citations

Li, Xiaoshan, Qubo Chen, Liming Lu, et al.. (2019). Chinese herbal medicine bi min fang for allergic rhinitis: protocol for a double-blind, double-dummy, randomized controlled trial. Trials. 20(1). 66–66. 2 indexed citations

Johnson, Danielle P., Samuel Bennett, Simon S. Jones, et al.. (2017). HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia. 32(1). 49–60. 34 indexed citations

Wang, Zhiqiang & Wenyong Chen. (2016). A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations. Methods in molecular biology. 1465. 149–157. 1 indexed citations

Reverchon, Maxime, et al.. (2016). VISFATIN (NAMPT) Improves in Vitro IGF1-Induced Steroidogenesis and IGF1 Receptor Signaling Through SIRT1 in Bovine Granulosa Cells1. Biology of Reproduction. 94(3). 54–54. 72 indexed citations

10.

Wang, Zhiqiang, Zheng Liu, Xiwei Wu, et al.. (2014). ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance. PLoS Genetics. 10(6). e1004414–e1004414. 27 indexed citations

11.

Chen, Wenyong, et al.. (2013). Sirtuins in Hematological Aging and Malignancy. Critical Reviews™ in Oncogenesis. 18(6). 531–547. 23 indexed citations

12.

Nam, Sangkil, Anna Scuto, Fan Yang, et al.. (2012). Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Molecular Oncology. 6(3). 276–283. 59 indexed citations

13.

Li, Ling, Lisheng Wang, Liang Li, et al.. (2012). Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib. Cancer Cell. 21(2). 266–281. 327 indexed citations

14.

Wang, Zhiqiang, Hongfeng Yuan, Michael Roth, et al.. (2012). SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene. 32(5). 589–598. 87 indexed citations

15.

Hasan, Md Kamrul, et al.. (2010). NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene. 30(8). 907–921. 201 indexed citations

16.

Yuan, Hongfeng, Zhiqiang Wang, Wengang Chen, et al.. (2009). BCR-ABL Gene Expression Is Required for Its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia. Journal of Biological Chemistry. 285(7). 5085–5096. 41 indexed citations

17.

Chen, Wenyong, David H. Wang, Ray-Whay Chiu Yen, et al.. (2005). Tumor Suppressor HIC1 Directly Regulates SIRT1 to Modulate p53-Dependent DNA-Damage Responses. Cell. 123(3). 437–448. 530 indexed citations breakdown →

18.

Chen, Wenyong, Timothy K. Cooper, Cynthia A. Zahnow, et al.. (2004). Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell. 6(4). 387–398. 130 indexed citations

19.

Chen, Wenyong & Stephen B. Baylin. (2004). Inactivation of Tumor Suppressor Genes: Choice Between Genetic and Epigenetic Routes. Cell Cycle. 4(1). 10–12. 14 indexed citations

20.

Chen, Wenyong & O.P. Bahl. (1993). High expression of the hormone binding active extracellular domain (1–294) of rat lutropin receptor in Escherichia coli. Molecular and Cellular Endocrinology. 91(1-2). 35–41. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact